Summary The dose limiting toxicities of the short infusion trial of the dacarbazine analog, CB1O-277, were nausea and vomiting which appeared to be related to the peak plasma level of the parent drug. In addition, based on mouse studies, these dose limiting toxicities occurred at a less than optimal level of the monomethyl metabolite, the presumed species required for antitumour activity. An The initial Phase I trial of CB10-277 was the starting point of the drug's clinical investigations. As with dacarbazine (Chabner, 1982) there was no preclinical evidence for schedule dependant activity with CB10-277. The short infusion schedule was the initial trial because it was the simplest and least costly with regards to patient and staff resources compared to other schedules. The accompanying manuscript contains additional rationale, results and discussion of the initial trial. The dose limiting toxicity (DLT) when given by short infusion (5-35 min), was nausea and vomiting and the maximum tolerated dose (MTD) was 6,000 mg m-2. Evidence for antitumour activity was observed in the form of responses (complete, partial and mixed) in patients with melanoma or sarcoma. Since the active species of CB10-277 is its monomethyl metabolite, levels of this metabolite were measured in addition to those of the parent compound. It was clear from the pharmacokinetic studies that the mean monomethyl metabolite area under the concentration x time curve (AUC) value in patients treated at the MTD (3 mM x minutes) was less than that predicted, based on the monomethyl metabolite AUC value at the mouse LD1O (8 mM x minutes). The lower monomethyl metabolite AUC in patients occurred despite a much higher mean CBlO-277 AUC at the MTD (573 mM x minutes) compared to that observed at a dose approximating to the mouse LDIO (142 mM x minutes). Thus, the monomethyl metabolite AUC values were lower in patients than predicted. However, since the mean monomethyl metabolite levels suggested a dose related increase over the range of 900-6,000 mg m-2; further CB10-277 dose escalation might be expected to ultimately yield monomethyl metabolite levels equivalent to those in mice.
The initial Phase I trial of CB10-277 was the starting point of the drug's clinical investigations. As with dacarbazine (Chabner, 1982) there was no preclinical evidence for schedule dependant activity with CB10-277. The short infusion schedule was the initial trial because it was the simplest and least costly with regards to patient and staff resources compared to other schedules. The accompanying manuscript contains additional rationale, results and discussion of the initial trial. The dose limiting toxicity (DLT) when given by short infusion (5-35 min), was nausea and vomiting and the maximum tolerated dose (MTD) was 6,000 mg m-2. Evidence for antitumour activity was observed in the form of responses (complete, partial and mixed) in patients with melanoma or sarcoma. Since the active species of CB10-277 is its monomethyl metabolite, levels of this metabolite were measured in addition to those of the parent compound. It was clear from the pharmacokinetic studies that the mean monomethyl metabolite area under the concentration x time curve (AUC) value in patients treated at the MTD (3 mM x minutes) was less than that predicted, based on the monomethyl metabolite AUC value at the mouse LD1O (8 mM x minutes). The lower monomethyl metabolite AUC in patients occurred despite a much higher mean CBlO-277 AUC at the MTD (573 mM x minutes) compared to that observed at a dose approximating to the mouse LDIO (142 mM x minutes). Thus, the monomethyl metabolite AUC values were lower in patients than predicted. However, since the mean monomethyl metabolite levels suggested a dose related increase over the range of 900-6,000 mg m-2; further CB10-277 dose escalation might be expected to ultimately yield monomethyl metabolite levels equivalent to those in mice.
In addition to quantitative differences in CB10-277 dose tolerance (human MTD = 6,000 mg m 2, mouse LDIO approximately 800 mg m-2), parent drug and metabolite AUC levels; quantitative differences in toxicity between mice and patients treated with short i.v. infusion were observed. In particular, the major toxicity observed in mice at the LDIO, i.e., leucopenia, was not detected in patients. Although the exact reason(s) for the toxicity differences was not known, it was speculated that the nausea and vomiting in patients may be in part due to the peak plasma level of CB10-277. Therefore, a dosing schedule that would allow a decrease in peak plasma CB10-277 levels might allow more total drug to be delivered per treatment course. If more total drug could be delivered, then more monomethyl metabolite might be formed. Two possible schedules for the second Phase I trial were considered, i.e., daily short infusions for five consecutive days (the most widely used schedule for dacarbazine treatment) and 24 h continuous infusion. 60, 120, 240, 360, 720, 1440, 1445, 1450, 1455, 1470, 1560 and 1680 min after starting the first 1,000 ml infusion. Twenty-four hour urine collections were obtained from some patients both prior to and following The dose range of 4,700-15,000 mg m-2 was studied in four escalations using 25-50% increments over the previous dose level until the last level. The dose levels, number of patients and courses administered with pharmacokinetics are shown in Table II .
Toxicities
The frequency and severity of gastrointestinal toxicities are shown in Table III . Although many patients had grade 3 nausea and vomiting, it resolved within 1 h after completion of the infusion and thereafter patients were able to eat. Some patients had diarrhoea during the drug infusion. Although diarrhoea was clearly drug related, it was not observed with the majority of courses and was grade 3 in only two (different patients).
Myelosuppression was observed in four of eight courses (four of five patients) treated at 12,000 mg m-2. None of these patients were heavily pretreated with myelosuppressive therapy. Both leucopenia and thrombocytopenia, as shown in Table IV were detected. In three of the four patients the observed myelosuppression nadir occurred after the second week (leucopenia nadir day = 18, 24 and 28 with platelet count nadir day = 18, 21, 21, respectively). In one patient the myelosuppression nadir for leucocytes and platelets occurred on day 7. Unfortunately, the two patients treated at 15,000 mg m-2 died suddenly (one on day 3, one on day 10). Although the cause of death for both patients was unknown, Figure 2 (Table VI) . However, the peak plasma level remained < 10 LM in all but one patient treated at 15,000 mg m 2 (Table VII) .
The parent drug was not detected in urine collections during the 24 h infusion period. Plasma triazene levels in a patient treated with 12,000 mg m-2 by 24 h continuous infusion are shown in Figure 3 . Discussion Acute toxic effects often limit the use of cytotoxic drugs. In particular nausea and vomiting are troublesome because of the extreme antisocial and psychological effects in addition to the physical discomfort caused to the patient. From the point of physical well being; nutrition, electrolyte and fluid balance can be compromised (Mitchell & Schein, 1984) . Psychologically, the inability to eat because of nausea and vomiting is a constant and unpleasant reminder to 'illness'. Table VII . (Gralla et al., 1981; Buchheit et al., 19. 1987; Grunberg et al., 1989;  Cubbeddu et a ly, highly effective antiemetic activity by blc tryptamine type III receptors has become av these were not licensed at the time that CB10-277 were done.
Dacarbazine is well known to its ability to induce severe nausea and vomiting. Some patients may develop tolerance of the drug administered on a daily x 5 schedule. Improve-, -ment in patient tolerance has also been reported when the ,' -amount of the initial dose is decreased (Moore & Meiselbaugh, 1976 at 12,000 mg m-2 where the mean AUC was 7 mM x minutes (AUC in Balb c mice near the mouse LD10 was 8 mM x minutes). The myelosuppression in one patient reversed within 5 days, but in the second patient it remained for 21 days. The first patient developed a transient fever (1 day) during the leucopenia; but no sequelae, except for treatment delay, was detected in the second patient.
Although there are various reports of dacarbazine induced myelosuppression (Cowan & Bergsagel, 1971; Johnson et al., 1976; Pritchard et al., 1980; Buesa et al., 1984) , the commonly used doses and schedules are associated with nausea, vomiting, diarrhoea, 'flu-like' syndrome, headache and hypersensitivity reactions and are not routinely associated with myelosuppression. Therefore, the lack of myelosuppression with the commonly used doses and schedules suggest that the full therapeutic potential of decarbazine is not being exploited. It is likely that the nausea and vomiting of both CB10-277 and dacarbazine are quite similar when given by short infusion. Therefore, CB1O-277 appears to offer no toxicity advantage using the short infusion. However, because of the potential chemical instability of dacarbazine, 24 h continuous infusions are not employed. The nausea and vomiting produced by CB 10-277 using the 24 h infusion is manageable and the cost in patient and staff resources is clearly less than the daily x 5 schedule frequently used for dacarbazine treatment. Using the 24 h continuous infusion schedule does appear to offer a toxicity advantage and certainly offers a cost advantage over dacarbazine.
The CB1O-277 schedule and dose recommended for further studies, including Phase II, is 12,000mgm-2 by 24 h continous infusion. This schedule was better tolerated than short infusion, the patient's hospital stay remained brief (24-28 h), acceptable myelosuppression was produced in the majority of patients and this dose was associated with production of the highest levels of monomethyl metabolite. A Phase II study of CBIO-277 in patients with melanoma has been undertaken by the Cancer Research Campaign Phase II group.
